食管癌免疫治疗研究进展

doi:10.11904/j.issn.1002-3070.2021.01.008

Abstract

Abstract: Esophageal cancer(EC)is a highly aggressive malignant tumor with a poor prognosis.In 2018,the incidence of EC is ranked the seventh in the world,and the sixth in the mortality.New cases of EC in China account for 54.1% of new cases worldwide,and deaths account for 56% of global deaths.Currently,standard treatment options for EC include surgery,radiotherapy,and chemotherapy.Despite the use of multidisciplinary therapies,the prognosis of EC patients is still unsatisfactory.The 5-year overall survival rate is only 30% to 40%.Immunotherapy,as a new treatment method,provides new treatment ideas for a variety of malignant tumors,and has greatly improved the prognosis of patients with malignant melanoma,non-small cell lung cancer and other tumor patients.Many phase Ⅱ/Ⅲ clinical trials have confirmed that immunotherapy combined with radiochemotherapy can enhance the anti-tumor effect.This article discusses the current clinical research of immunotherapy in EC.

Key words: Esophageal cancer, Immunity therapy, Pabolizumab, Nivolumab, Ipilimumab

CLC Number:

R735.1

LI Ruiyang,FANG Lin,ZHANG Yanqiao. Research progress on immunotherapy of esophageal cancer[J]. Journal of Practical Oncology, 2021, 35(1): 41-45.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2021.01.008

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2021/V35/I1/41

References

1 Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.
2 杜灵彬,魏文强.中国人群食管鳞癌生存分析研究新进展[J].实用肿瘤学杂志,2018,32(4):344-348.
3 Ferlay J,Soerjomataram I,Dikshit R,et al.Cancer incidence and mortality worldwide:sources,methods and major patterns in GLOBOCAN 2012[J].Int J Cancer,2015,13(6):359-386.
4 Karlsson AK,Saleh SN.Checkpoint inhibitors for malignant melanoma:A systematic review and meta-analysis[J].Clin Cosmet Investig Dermatol,2017,24(10):325-339.
5 Herzberg B,Campo MJ,Gainor JF.Immune checkpoint inhibitors in non-small cell lung cancer[J].Oncologist,2017,22(1):81-88.
6 Weichselbaum RR,Liang H.Radiotherapy and immunotherapy:A beneficial liaison?[J].Nat Rev Clin Oncol,2017,14(6):365-379.
7 Aoto K,Mimura K,Okayama H,et al.Immunogenic tumor cell death induced by chemotherapy in patients with breast cancer and esophageal squamous cell carcinoma[J].Oncol Rep,2018,39(1):151-159.
8 Kroemer G,Galluzzi L,Kepp O.Immunogenic cell death in radiation therapy[J].Annu Rev Immunol,2013,2(10):51-72.
9 Hong MH,Kim HR,Park SY,et al.A phase Ⅱ trail of preoperative chemoradiotherapy and pembrolizumab for locally advanced esophageal squamous cell carcinoma(ESCC)[J].J Clin Oncol,2019,37(15):4027.
10 Hirva M,Bryan JS,Laith IA,et al.Safety and efficacy of durvalumab following multimodality therapy for locally advanced esophageal and GEJ adenocarcinoma:results from big ten cancer research consortium study[J].J Clin Oncol,2019,37(15):e16070.
11 Kitagawa Y,Doki Y,Kato K,et al.Two year survival and safety update for esophageal squamous cell carcinoma treated with nivolumab[J].Ann Oncol,2017,28(5):209-268.
12 Yuriy Y,Alexander PO,Calvo E,et al.Nivolumab ± ipilimumab in pts with advanced(adv)/metastatic chemotherapy-refractory(CTx-R)gastric(G),esophageal(E),or gastroesophageal junction(GEJ)cancer:CheckMate 032 study[J].J Clin Oncol,2017,35(15):4014.
13 Greally M,Molena D,Sihag S,et al.Phase Ib/II trial of durvalumab and chemoradiation(CRT)with carboplatin/paclitaxel for esophageal and gastroesophageal junction(GEJ)adenocarcinoma[J].J Clin Oncol,2018,36(4):172.
14 Chung HC,Arkenau HT,Wyrwicz L,et al.Safety,PD-L1 expression,and clinical activity of avelumab(MSB0010718C),an anti-PD-L1 antibody,in patients with advanced gastric or gastroesophageal junction cancer[J].J Clin Oncol,2016,34(4):167.
15 Smyth E,Thuss-Patience PC.Immune checkpoint inhibition in gastro-oesophageal cancer[J].Oncol Res Treat,2018,41(5):272-280.
16 Bang Y,Golan T,Lin CC,et al.Interim safety and clinical activity in patients(pts)with locally advanced and unresectable or metastatic gastric or gastroesophageal junction(G/GEJ)adenocarcinoma from a multicohort phase I study of ramucirumab(R)plus durvalumab(D)[J].J Clin Oncol,2018,36(4):92.
17 Vrána D,Matzenauer M,Melichar B.Current status of checkpoint inhibitors in the treatment of esophageal and gastric tumors-verview of studies[J].Klin Onkol,2017,31(1):35-39.
18 Doi T,Piha-Paul SA,Jalal SI,et al.Pembrolizumab(MK-3475)for patients(pts)with advanced esophageal carcinoma:preliminary results from KEYNOTE-028[J].J Clin Oncol,2015,33(15):4010.
19 Doi T,Bennouna J,Shen L,et al.NOTE-181:phase 3,open-label study of second-line pembrolizumab vs single-agent chemotherapy in patients with advanced/metastatic esophageal adenocarcinoma[J].J Clin Oncol,2017,37(4):2.
20 Kato K,Satoh T,Muro K,et al.A subanalysis of Japanese patients in a randomized,double-blind,placebo-controlled,phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to,or intolerant of,at least two previous chemotherapy regimens(ONO-4538-12,ATTRACTION-2)[J].Gastric Cancer,2019,22(2):344-354.
21 Li W,Wei Z,Yang X,et al.Salvage therapy of reactive capillary hemangiomas:apatinib alleviates the unique adverse events induced by camrelizumab in non-small cell lung cancer[J].Cancer Res Ther,2019,15(7):1624-1628.
22 Teng Y,Guo RF,Sun JF,et al.Reactive capillary hemangiomas induced by camrelizumab(SHR-1210),an anti-PD-1 agent[J].Acta Oncol,2019,58(3):388-389.
23 Shah MA,Kojima T,Enzinger PC,et al.Pembrolizumab for patients with previously treated metastatic adenocarcinoma or squamous cell carcinoma of the esophagus:phase 2 keynote-180 study[J].J Clin Oncol,2018,36(15):4049.
24 Tabernero J,Cutsem EV,Bang Y,et al.Pembrolizumab with or without chemotherapy versus chemotherapy for first-line treatment of advanced gastric or gastroesophageal junction(G/GEJ)adenocarcinoma:The Phase 3 KEYNOTE-062 Study[J].Ann Oncol,2019,30(4):152-153.
25 Ajani JA,D'Amico TA,Bentrem DJ,et al.Esophageal and esophagogastric junction cancers,version 2.2019,NCCN clinical practice guidelines in oncology[J].J Natl Compr Canc Netw,2019,17(7):855-883.
26 Liang F.The KEYNOTE-061 trial[J].Lancet,2019,393(10176):1098.
27 Fuchs CS,Doi T.Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer:phase 2 clinical KEYNOTE-059 trial[J].JAMA Oncology,2018,4(5):e180013.

[1]	ZHAO Nannan, QIN Wen, HAN Yonghuan, LU Jing, LI Yamin, XU Yajun. Effects of SOX11 on inhibiting proliferation and migration of esophageal cancer cells [J]. Journal of Practical Oncology, 2020, 34(1): 17-23.
[2]	LIU Zhongyang, YUAN Xin, ZHOU Wen, LI Xiaoliang, FAN Limao. Therapeutic effect of minimally invasive small incision surgery on patients with early thoracic esophageal cancer and its influence in pain [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(1): 57-61.
[3]	YU Fang, ZHAO Pei. The role and mechanism of TRAP1 in the development of esophageal cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(6): 515-519.
[4]	DU Lingbin,WEI Wenqiang. Progress research in survival analysis of esophageal squamous cell carcinoma(ESCC)in Chinese population [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(4): 344-348.
[5]	JIN Jing,HE Yutong. Research progress of miR-21 in esophageal cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(3): 277-280.
[6]	GAO Shile,HU Zongtao,DONG Liuyi,WANG Chong,LV Donglai,ZHENG Chun. One case on esophageal cancer accompanied with eyeball and liver metastasis [J]. PRACTICAL ONCOLOGY JOURNAL, 2015, 29(4): 347-349.
[7]	QIU Zidan,LI Jiancheng. Molecular targeted therapy for esophageal cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2015, 29(1): 57-60.
[8]	TANG Xiaojun,LIU Gaohua,WANG Xiaoyong,ZHAN Fusheng. Effect of mediastinal drainage on treatment of intra-thoracic anastomotic leak in post operation of esophageal cancer patients [J]. PRACTICAL ONCOLOGY JOURNAL, 2014, 28(6): 535-539.
[9]	YIN Hongtao,E Mingyan,WANG Muhong,ZHANG Yan. Clinical factors and their curative effect analysis in elderly esophageal cancer patients with radiotherapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2012, 26(3): 236-240.
[10]	ZHANG Yuxue,WU Haiyan,LI Huiyan. The meta-analysis between p53 alteration and smoking,alcohol consumption in esophageal cancer among Chinese population [J]. PRACTICAL ONCOLOGY JOURNAL, 2011, 25(4): 315-318.
[11]	WU Yan, ZHANG Yan, XU Ji, LU Yingzhi. Evaluation of combined docetaxel and nedaplatin chemotherapy for advanced esophageal cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2010, 24(1): 38-40.
[12]	WANG Jian, SUN Suping, ZHANG Xuguang, NI Xinchu, YU Jingping, LI Yi. Side effects contrasting of nedaplatin plus 5-Fu and cisplatin plus 5-Fu combined with synchronous radiotherapy on esophageal cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2009, 23(6): 513-515.
[13]	GAO Fei, JIA Lin, DU Huizhang, WANG Yun, KUANG Xiaohong, HAN Jianjun. A clinical study of combination of radiotherapy and IP regimen in the treatment of patients with local advanced esophageal cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2009, 23(2): 126-129.

Research progress on immunotherapy of esophageal cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 13

Recommended Articles

Metrics

Comments